Literature DB >> 7533768

Expression of fibroblast growth factors in thyroid cancer.

M C Eggo1, J M Hopkins, J A Franklyn, G D Johnson, D S Sanders, M C Sheppard.   

Abstract

We have examined immunoreactive fibroblast growth factor-1 (FGF-1) and FGF-2 in thyroid sections from normal tissue, follicular adenoma, differentiated follicular and papillary carcinoma, and anaplastic carcinoma. Polyclonal primary antibodies (Dr. A. Baird, Whittier Institute, La Jolla, CA) to FGF-1 and FGF-2 and fluorescein-conjugated secondary antibodies were used with confocal microscopy to allow quantitation and subcellular localization of the antigens. Staining for FGF-1 and FGF-2 was intense in the differentiated malignant tumor specimens, whereas staining in the normal thyroid tissue controls was not detectable above background fluorescence. Staining for FGF-1 and FGF-2 was intracellular and was not found in the nucleus. Staining using either antibody was enhanced in follicular adenomas, but was less intense than that in the malignant tumors. Sections from anaplastic carcinomas also stained positively. In primary cultures of thyroid cells derived from a papillary carcinoma, staining for FGF-2 was 10-fold greater than that from normal thyroid cells from the same patient. The data suggest a possible role for FGFs in the etiology of thyroid carcinoma.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7533768     DOI: 10.1210/jcem.80.3.7533768

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  11 in total

1.  Research resource: Comprehensive expression atlas of the fibroblast growth factor system in adult mouse.

Authors:  Klementina Fon Tacer; Angie L Bookout; Xunshan Ding; Hiroshi Kurosu; George B John; Lei Wang; Regina Goetz; Moosa Mohammadi; Makoto Kuro-o; David J Mangelsdorf; Steven A Kliewer
Journal:  Mol Endocrinol       Date:  2010-07-28

2.  Expression of fibroblast growth factor-1 and fibroblast growth factor-2 in normal liver and hepatocellular carcinoma.

Authors:  N H Chow; K S Cheng; P W Lin; S H Chan; W C Su; Y N Sun; X Z Lin
Journal:  Dig Dis Sci       Date:  1998-10       Impact factor: 3.199

3.  Iodine deficiency induces a thyroid stimulating hormone-independent early phase of microvascular reshaping in the thyroid.

Authors:  Anne-Catherine Gérard; Sylvie Poncin; Bertrand Caetano; Pierre Sonveaux; Jean-Nicolas Audinot; Olivier Feron; Ides M Colin; Fabrice Soncin
Journal:  Am J Pathol       Date:  2008-02-14       Impact factor: 4.307

4.  Thyroid follicular oncogenesis in iodine-deficient and iodine-sufficient areas: search for alterations of the ras, met and bFGF oncogenes and of the Rb anti-oncogene.

Authors:  L Bartolone; F Vermiglio; M D Finocchiaro; M A Violi; D French; A Pontecorvi; F Trimarchi; S Benvenga
Journal:  J Endocrinol Invest       Date:  1998-11       Impact factor: 4.256

Review 5.  Estrogens and stem cells in thyroid cancer.

Authors:  Mariangela Zane; Veronica Catalano; Emanuela Scavo; Marco Bonanno; Maria Rosa Pelizzo; Matilde Todaro; Giorgio Stassi
Journal:  Front Endocrinol (Lausanne)       Date:  2014-07-25       Impact factor: 5.555

6.  A multiplexed, targeted mass spectrometry assay of the S100 protein family uncovers the isoform-specific expression in thyroid tumours.

Authors:  Juan Martínez-Aguilar; Roderick Clifton-Bligh; Mark P Molloy
Journal:  BMC Cancer       Date:  2015-03-29       Impact factor: 4.430

Review 7.  Insulin Resistance: Any Role in the Changing Epidemiology of Thyroid Cancer?

Authors:  Roberta Malaguarnera; Veronica Vella; Maria Luisa Nicolosi; Antonino Belfiore
Journal:  Front Endocrinol (Lausanne)       Date:  2017-11-14       Impact factor: 5.555

8.  Integrated data analysis reveals potential drivers and pathways disrupted by DNA methylation in papillary thyroid carcinomas.

Authors:  Caroline Moraes Beltrami; Mariana Bisarro Dos Reis; Mateus Camargo Barros-Filho; Fabio Albuquerque Marchi; Hellen Kuasne; Clóvis Antônio Lopes Pinto; Srikant Ambatipudi; Zdenko Herceg; Luiz Paulo Kowalski; Silvia Regina Rogatto
Journal:  Clin Epigenetics       Date:  2017-05-02       Impact factor: 6.551

9.  MiR-195 Inhibits Tumor Growth and Metastasis in Papillary Thyroid Carcinoma Cell Lines by Targeting CCND1 and FGF2.

Authors:  Yali Yin; Shubin Hong; Shuang Yu; Yanrui Huang; Shuwei Chen; Yujie Liu; Quan Zhang; Yanbing Li; Haipeng Xiao
Journal:  Int J Endocrinol       Date:  2017-06-27       Impact factor: 3.257

Review 10.  Multikinase inhibitors in the treatment of thyroid cancer: specific role of lenvatinib.

Authors:  Neda Stjepanovic; Jaume Capdevila
Journal:  Biologics       Date:  2014-04-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.